Dongsung Pharmaceutical is undergoing court rehabilitation and on April 14, 2026, received court approval to appoint 4 new outside directors.
The new outside directors include two partners from accounting firms, a lawyer from a law firm, and a professor from Seoul National University, enhancing expertise and independence.
The board now consists of 7 registered directors including 4 outside directors, achieving an outside ratio of 57%.
Although the company is in rehabilitation, the strengthened governance may enhance recovery prospects and improve shareholder value.
[AI Summary]Dongsung Pharmaceutical, under court rehabilitation, has appointed four experienced outside directors with court approval, significantly improving board independence and transparency. This move enhances credibility of the rehabilitation plan and could positively impact stock price.
KOSPI Filing Information
Filing: Report on Appointment, Dismissal or Mid-Term Resignation of Outside Directors